Publication at Faculty of Medicine in Hradec Králové |
2016
Abstract
Dimethyl fumarate is registered for treatment relapsing-remitting multiple sclerosis in the Czech Republic. It has a new mechanism of action and optimal pharmacokinetic profile with no clinically relevant drug-drug interactions.The efficacy of dimenthyl fumarate has been proven in several clinical trials.
The treatment with this drug is quite well tolerated, the most common adverse events include flushing and gastrointestinal disorders.